Caribou Biosciences
CRBU | NASDAQ
$0.49
-$0.04 (-8.03%)
At close: Oct 26, 2026, 4:00 PM ET
-8.03%
(1D)Rating
Key Statistics
Market Data
Market Cap $52.77M
1D Range
0.49 0.54
52W Range
0.46 2.50
Valuation (TTM)
PE -0.45
PB 0.54
EV/EBITDA 0.32
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $1.00
Cash Flow
FCF Yield -181.5%
SBC Adj. FCF Yield -201.4%
SBC Impact -11.0%
Margins
Gross Margin -129.7%
Operating Margin -1090.9%
FCF Margin -954.2%
Growth (CAGR)
Revenue 3Y | 5Y -11.0% |
13.9%
Dil EPS 3Y | 5Y 10.9% |
6.2%
FCF 3Y | 5Y 15.2% |
-5.4%
Returns
ROA -72.4%
ROE -89.1%
ROIC -86.3%
Financial Health
Net Cash
$112.31M
Current Ratio 6.49
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address b...
Sector Healthcare
Industry Biotechnology
Employees 97
IPO Date Jul 23, 2021
Website cariboubio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
7
Consensus
Hold
Price Target
$1.00
Upside
+104.08%
Buy (3)
Hold (4)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CRBU